PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
about
A perspective on the impact of radiation therapy on the immune rheostat.PD-L1 immune suppression in cancer: Tumor cells or host cells?Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution.Immune checkpoint inhibitors in advanced non-small cell lung cancer.The diverse functions of the PD1 inhibitory pathway.A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.Inhibitors of the PD-1 Pathway in Tumor Therapy.Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.Mechanisms of resistance to immune checkpoint inhibitors.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.The host protecting the tumor from the host - targeting PD‑L1 expressed by host cells.PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?Interferon Signaling Is Frequently Downregulated in Melanoma.Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK ActivationDeficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasisThe intracellular signalosome of PD-L1 in cancer cellsDifferential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
P2860
Q38679488-16B641CF-24D2-4DA2-9DF5-814B6554759BQ41252211-4337C613-7A9E-4FA6-A0D7-B8DE46FBF634Q41369044-D7BADC31-9266-4881-82E8-D73D1710CCB4Q47120629-93470CA5-46D9-4AE1-A08D-D1842CE0E4DFQ47285613-786D1D1C-99E7-4BFF-B61F-BF8C9A4D364EQ47433391-ECB3B779-CEA7-4433-A04A-D26F8E238D92Q47563451-DE0913DB-6879-4889-91CC-3B399FA5A440Q47678849-7B110A51-867B-4C59-B583-A137FE802A31Q48256829-7599DC47-5CDA-4A61-BE9A-DB14F99799CEQ48293633-6AADB052-F1FD-43D8-990C-219411F6620BQ48689919-57869BC0-3B42-4F56-8000-C9C99BCBA87EQ49374190-9BAB0E64-8945-49CC-B25A-C20FEC7B259FQ49537326-5C0FD72D-C97E-4D96-BF70-49D0B6188AC1Q49551908-0560D147-1627-440C-930A-56503CDA4FCAQ50031833-E48FC429-7B57-4E5B-ADAE-D40C9A61629AQ50031857-5C0C385C-08A6-4151-A2D6-D0D9DE6B2AA1Q50031872-E6DC3150-9B17-480E-AA88-71FE38431DF9Q52717528-C95D598F-609B-40CE-A219-9E1B5BCA0E96Q54961397-9D112B24-9D9C-4626-A75E-662AFC6868E4Q55049458-81187F37-AD14-4F94-BC6C-2D441320A72CQ55209751-07A76098-E3C9-4D04-B02E-21F1C0C6E3BBQ55446596-EDE44BD9-A674-4691-92FF-4E7ED30BA1DFQ55518179-1BBD9374-6504-4CCE-B7DF-AF9D520D0290Q56761471-A6CE764E-8BB7-4F1F-A2FE-8E398FF0A7EBQ56892731-306A9DFE-C852-488A-9937-C36B752EFC68Q57067759-CB8C4FD3-7A6B-4CD6-8E3B-9034AC09E30BQ57295962-B3EB3D43-4D3E-4D87-B38F-8A63254B1689Q58617565-8887354F-D21D-4D6F-80FA-1DE9B6A67E59
P2860
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
PD-L1 on tumor cells is suffic ...... ibits CD8 T cell cytotoxicity.
@en
type
label
PD-L1 on tumor cells is suffic ...... ibits CD8 T cell cytotoxicity.
@en
prefLabel
PD-L1 on tumor cells is suffic ...... ibits CD8 T cell cytotoxicity.
@en
P2093
P2860
P50
P356
P1476
PD-L1 on tumor cells is suffic ...... hibits CD8 T cell cytotoxicity
@en
P2093
Kathleen A McGuire
Martin W LaFleur
Robert T Manguso
Vikram R Juneja
W Nicholas Haining
P2860
P304
P356
10.1084/JEM.20160801
P407
P577
2017-03-16T00:00:00Z